嵌合抗原受体介导的抗肿瘤细胞治疗的发展

Progression of chimeric antigen receptor-mediated antitumor cell-based therapy

摘要:

嵌合抗原受体（Chimeric Antigen Receptor，CAR）技术驱动的T细胞疗法在肿瘤治疗中展示了巨大的创新潜力，尤其在血液肿瘤方面取得了显著成果。通过精准改造患者或供体细胞，使其能够特异性识别并清除肿瘤细胞，此策略已进入临床实践的新阶段。尽管如此，CAR-T细胞疗法在实体瘤治疗中的效果尚未达到预期，并且其潜在的不良反应仍引起广泛关注。随着科技的不断进步，基于CAR技术改造的多种细胞类型，如NK细胞、巨噬细胞、NKT细胞及γδT细胞等，正在被纳入肿瘤治疗研究，拓展了治疗前景。本综述深入探讨了CAR技术的最新进展及其在细胞疗法中的应用，为抗肿瘤治疗提供潜在的新思路和可能性。

Abstract:

Chimeric Antigen Receptor (CAR) technology-driven T cell therapies have demonstrated great potential for innovation in oncology treatment, with notable results especially in hematological tumors. By precisely modifying patient or donor cells to specifically recognize and remove tumor cells, this strategy has entered a new phase of clinical practice. Nevertheless, CAR-T cell therapy has not yet achieved the expected results in the treatment of solid tumors, and its potential adverse effects are still a cause for widespread concern. With the continuous advancement of science and technology, multiple cell types modified based on CAR technology, such as NK cells, macrophages, NKT cells, and γδT cells, are being incorporated into tumor therapeutic studies, expanding the therapeutic outlook. This review delves into the latest advances in CAR technology and its application in cell therapy, providing potential new ideas and possibilities for anti-tumor therapy.